Feed Top Reports Pricing

⌘K

07:14:57·86d

ANALYSTRating

Barclays resumed coverage on 4D Molecular Therapeutics with a new price target

FDMT· 4D Molecular Therapeutics Inc.

Health Care

Original source

Companies

FDMT
4D Molecular Therapeutics Inc.
Health Care

Recent analyst ratings

Jan 28UpdateBarclays$33.00
Nov 7UpdateMorgan Stanley-
Jan 13UpdateBMO Capital Markets$15.00
Nov 21UpdateMorgan Stanley$8.00
Sep 23UpdateCantor Fitzgerald-
Apr 15UpdateBarclays$45.00

Related

PR6d
4DMT Announces New Employment Inducement Grants
SEC16d
Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.
SEC24d
4D Molecular Therapeutics Inc. filed SEC Form 8-K: Leadership Update
INSIDER27d
SEC Form 4 filed by Simms Christopher Paul
INSIDER27d
SEC Form 4 filed by Kirn David
INSIDER27d
SEC Form 4 filed by Bizily Scott
SEC29d
Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.
INSIDER30d
SEC Form 4 filed by Gupta Ashoo

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022